23 November 2017
News and Views
Links and Services
The latest Alimentary Pharmacology & Therapeutics compares infliximab and immunosuppressant therapy with infliximab alone for active ulcerative colitis.
The benefit of the combination of infliximab and immunosuppressant therapy is debated in ulcerati
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors